Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
BMC Pharmacol Toxicol ; 24(1): 81, 2023 12 21.
Artigo em Inglês | MEDLINE | ID: mdl-38129872

RESUMO

BACKGROUND: Quercetin (QC) possesses a variety of health-promoting effects in pure and in conjugation with nanoparticles. Since the mRNA-SIRT1/p66Shc pathway and microRNAs (miRNAs) are implicated in the oxidative process, we aimed to compare the effects of QC and QC-conjugated superparamagnetic iron oxide nanoparticles (QCSPIONs) on this pathway. METHODS: Through the use of the chemical coprecipitation technique (CPT), SPIONs were synthesized, coated with dextran, and conjugated with quercetin. Adult male Wistar rats were given intraperitoneal injections of streptozotocin to look for signs of type 1 diabetes (T1D). The animals were randomized into five groups: the control group got deionized water (DI), free QC solution (25 mg/kg), SPIONs (25 mg/kg), and QCSPIONs (25 mg/kg), and all groups received repeat doses administered orally over 35 days. Real-time quantitative PCR was used to assess the levels of miR-34a, let-7a-p5, SIRT1, p66Shc, CASP3, and PARP1 expression in the hippocampus of diabetic rats. RESULTS: In silico investigations identified p66Shc, CASP3, and PARP1 as targets of let-7a-5p and miR-34a as possible regulators of SIRT1 genes. The outcomes demonstrated that diabetes elevated miR-34a, p66Shc, CASP3, and PARP1 and downregulated let-7a-5p and SIRT1 expression. In contrast to the diabetic group, QCSPIONs boosted let-7a-5p expression levels and consequently lowered p66Shc, CASP3, and PARP1 expression levels. QCSPIONs also reduced miR-34a expression, which led to an upsurge in SIRT1 expression. CONCLUSION: Our results suggest that QCSPIONs can regulate the SIRT1/p66Shc-mediated signaling pathway and can be considered a promising candidate for ameliorating the complications of diabetes.


Assuntos
Disfunção Cognitiva , Diabetes Mellitus Experimental , MicroRNAs , Ratos , Masculino , Animais , Ratos Wistar , Quercetina/farmacologia , Proteína 1 de Transformação que Contém Domínio 2 de Homologia de Src/metabolismo , Caspase 3/metabolismo , Diabetes Mellitus Experimental/genética , Sirtuína 1/genética , Sirtuína 1/metabolismo , MicroRNAs/genética , MicroRNAs/metabolismo , Nanopartículas Magnéticas de Óxido de Ferro
2.
J Nanobiotechnology ; 19(1): 327, 2021 Oct 18.
Artigo em Inglês | MEDLINE | ID: mdl-34663344

RESUMO

Iron oxide nanoparticles (IONPs) have been proposed as targeted carriers to deliver therapeutic molecules in the central nervous system (CNS). However, IONPs may damage neural tissue via free iron accumulation, protein aggregation, and oxidative stress. Neuroprotective effects of quercetin (QC) have been proven due to its antioxidant and anti-inflammatory properties. However, poor solubility and low bioavailability of QC have also led researchers to make various QC-involved nanoparticles to overcome these limitations. We wondered how high doses or prolonged treatment with quercetin conjugated superparamagnetic iron oxide nanoparticles (QCSPIONs) could improve cognitive dysfunction and promote neurogenesis without any toxicity. It can be explained that the QC inhibits protein aggregation and acts against iron overload via iron-chelating activity, iron homeostasis genes regulation, radical scavenging, and attenuation of Fenton/Haber-Weiss reaction. In this review, first, we present brain iron homeostasis, molecular mechanisms of iron overload that induced neurotoxicity, and the role of iron in dementia-associated diseases. Then by providing evidence of IONPs neurotoxicity, we discuss how QC neutralizes IONPs neurotoxicity, and finally, we make a brief comparison between QC and conventional iron chelators. In this review, we highlight that QC as supplementation and especially in conjugated form reduces iron oxide nanoparticles neurotoxicity in clinical application.


Assuntos
Encéfalo/efeitos dos fármacos , Nanopartículas Magnéticas de Óxido de Ferro/toxicidade , Fármacos Neuroprotetores/farmacologia , Neurotoxinas/toxicidade , Quercetina/farmacologia , Animais , Encéfalo/fisiologia , Modelos Animais de Doenças , Humanos , Ferro/metabolismo , Sobrecarga de Ferro , Camundongos , Doenças Neurodegenerativas , Ratos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...